For decades, our health care system has been tied to a fee-for-service model. This payment approach creates an incentive for providers to require patients to undergo additional tests that may not be necessary. We cannot afford to continue going down this road. Pfizer's Dr. Robert Popovian discusses an alternative — a return to a capitated payment model.
health care costs
The "American healthcare costs vs the rest of the world" narrative has been with us forever and this is unlikely to change. But it is not a simple problem, even though it is portrayed as just that. Pfizer's Dr. Robert Popovian takes his usual thoughtful look at thorny issues in his latest piece in Morning Consult. Don't miss.
Assembly Bill 3087 wants to put a cap on health care costs. If you ignore the yelling from proponents and opponents, you'll see it creates the same marketplace that we have for drugs, whose prices continue to rise with little benefit to the real purchasers. (That would be you and me.)
For the millions of Americans who delay or miss medical appointments annually due to transportation difficulties, the newly-launched ride service Uber Health hopes to improve their access to health care. This service allows hospitals and doctors to book rides for their patients for non-emergency visits.
In the no good deed goes unpunished department, California s Gilead Sciences has come under attack by Congressman Henry Waxman a perennial critic of the drug industry. In this case, the issue is the price of Gilead s Sovaldi one of the most revolutionary new drugs to come along in some time.
ACSH friend Dr. Henry Miller and economist Vasilios Tsimiklis wrote a spot-on piece published on forbes.com detailing the rising health care expenditures in industrialized countries and the necessity for